13 results about "Muscle loss" patented technology

The application discloses application of O-acyl-alpha-hydroxy acid compounds in weight loss and lipid reduction, and belongs to the fields of biological medicine manufacturing, biological medicine use and functional food development. The O-acyl-alpha-hydroxy acid compounds can inhibit weight growth of high-fat diet-induced obese model mice and reduce body fat. Compared with GLP-1 receptor weight loss drugs which achieve the effect of reducing weight by inhibiting appetite, the O-acyl-alpha-hydroxy acid compounds are not dependent on appetite inhibition, and can reduce side effects such as gastrointestinal discomfort and muscle loss caused by inhibiting appetite. When combined or sequentially administered with GLP-1 drugs, the O-acyl-alpha-hydroxy acid compounds can maintain or enhance the weight loss effect while improving the side effects caused by GLP-1, and can prevent the risk of significant weight rebound after stopping GLP-1 by maintaining body weight. The application provides a safe and effective new strategy for weight loss and lipid reduction.

This invention discloses a *Lactococcus faecium* strain, YS-IM01. This strain can efficiently hydrolyze sheep colostrum proteins and specifically release a large amount of leucine. This invention also provides a polypeptide composition comprising multiple active peptides with potential for muscle synthesis, immunomodulation, and antioxidant activity. This invention further provides a fermented sheep colostrum product obtained by fermenting sheep colostrum with the aforementioned *Lactococcus faecium*. This invention also provides a method for preparing the fermented sheep colostrum product, comprising steps including fermentation, low-temperature vacuum concentration, and vacuum freeze-drying. Simultaneously, this invention also provides a method for preparing a drug using *Lactococcus faecium* and the polypeptide composition to prevent and / or improve age-related muscle loss.

Provided herein are compositions and methods for tissue repair. In particular, the compositions and methods described herein find use in repairing, regenerating, and modulating fibrosis and inflammation in a variety of tissues such as, for example, large volume muscle loss, including skeletal and heart muscle, blast wave injury, muscle loss from diabetes and resulting from frailty as a result of aging.

The application discloses ecdysterone-low molecular weight fructan composite microspheres with fat-reducing and muscle-increasing functions, and a preparation method and application thereof, and belongs to the technical field of biological medicine and functional food. The composite microspheres have a core-shell structure, the inner core is a calcium alginate gel, the outer shell is chitosan, the inner core co-encapsulates ecdysterone and low molecular weight fructan, and the mass ratio of the two is 0.8-1.2:1. The preparation adopts a liquid drop microfluidic technology combined with an internal gelation method to form the inner core, and adopts a post-crosslinking method to coat the outer shell. The composite microspheres are regular in shape, uniform in particle size, high in encapsulation rate, good in stability, excellent in pH response slow-release and anti-degradation characteristics in the gastrointestinal tract. In-vivo pharmacological experiments prove that the composite microspheres can reduce the body weight and body fat rate of obese mice, increase the lean meat content and muscle strength, realize synergistic effects of fat reduction and muscle increase, and can be used for preparing drugs or functional food for improving obesity-related muscle loss, low-muscle obesity and related metabolic syndrome.

The present invention relates to probiotic compositions comprising at least one Lactobacillus helveticus, at least one Bifidobacterium longum, and at least one Bifidobacterium animalis. The present invention further relates to methods of using said compositions for preventing muscle loss, improving or maintaining muscle strength, and maintaining intestinal barrier integrity.

Provided is a composition for preventing, improving, or treating muscular disorders including sulfonamide-based compounds or salts thereof. According to the present disclosure, the sulfonamide-based compounds or salts thereof may prevent inhibition of differentiation of myoblasts by regulating the expression of PHF20 and YY1. Accordingly, since the composition may prevent or alleviate muscle loss, promote muscle regeneration, and improve muscle exercise function, balance ability, and grip strength recovery ability through increased muscles and changes in ratio of muscle fibers, the composition may be effectively used for therapeutic agents, foods, or feeds for preventing, improving or treating muscle disorders, and improving muscle functions or muscle mass.

The present invention relates to a novel therapeutic agent capable of treating muscle diseases, metabolic diseases, and bone diseases by simultaneously inhibiting the activin type II receptor and myostatin. Specifically, the invention relates to a bispecific protein comprising an anti-ActRII antibody and an anti-Myostatin antibody, and the use thereof. The simultaneous inhibition of the activin type II receptor and myostatin according to the present invention exhibits excellent effects of muscle growth and bone differentiation as well as weight loss; thus, it resolves the problem of muscle loss, which is a side effect of existing anti-obesity treatments, and can effectively improve various metabolic diseases. Therefore, the bispecific protein of the present invention can be utilized in various fields for the improvement and treatment of muscle diseases, metabolic diseases, and bone diseases.

The present application relates to a peptide having muscle loss inhibiting and muscle mass improving activity and use thereof, which provides a peptide consisting of the amino acid sequence of SEQ ID NO: 1, and a pharmaceutical composition for preventing or treating a muscle disease including the peptide as an effective ingredient and a food composition for preventing or improving a muscle disease including the peptide as an effective ingredient.

This invention belongs to the field of functional composition technology, and specifically relates to a composition for improving muscle loss and promoting muscle growth, and its application. The composition comprises leucine, lupin peptide, lactoferrin, and broccoli peptide, wherein the mass ratio of leucine, lupin peptide, lactoferrin, and broccoli peptide is (1~5):(1~5):(1~10):(1~10). It has been demonstrated that the combined intervention of these four specific components has a synergistic effect in improving muscle loss, promoting muscle growth, enhancing muscle performance, and regulating the expression of muscle metabolism-related factors, showing broad application prospects in improving muscle condition and function.

Provided herein are compositions, methods of manufacture, and methods of use thereof, wherein the compositions are emulsions comprising nitric oxide-increasing agents, as illustrative examples nitric oxide precursors and / or plant-based nitrate sources, for topical application that provide for sustained elevation of nitric oxide levels in the body. Methods of use include methods for preventing or reducing muscle loss that is correlated with a weight loss method, for example treatment with a GLP-1 agonist.

Provided is a pharmaceutical composition for preventing and treating muscle loss, comprising an oregonin compound derived from a plant of the genus Alnus as an active ingredient.

This invention discloses a strain of *Lactobacillus delbrueckii* with muscle-protecting function during fat loss, its products, and applications, belonging to the field of microbial technology. The invention discloses *Lactobacillus delbrueckii* subspecies Turb8, with accession number CGMCC No. 35627. This strain or its preparations can effectively prevent or improve muscle loss and functional decline during the use of fat-loss drugs such as GLP-1 receptor agonists (e.g., liraglutide, smegglutide), achieving the effect of "fat loss without muscle loss." While maintaining the original weight-loss effect of fat-loss drugs, the strain of this invention can significantly increase the user's lean body mass percentage, increase lower limb muscle mass, increase muscle fiber cross-sectional area, and improve muscle function indicators such as limb strength and suspension endurance. This invention also relates to bacterial agents containing this strain, various preparations, and their application in the preparation of products for improving (especially drug-induced) muscle loss.

This invention proposes a method for analyzing muscle tissue in sarcopenia patients based on CT images. The method includes acquiring abdominal CT images of the same subject; performing pixel-level segmentation on the preprocessed CT images to distinguish and locate muscle, subcutaneous fat, and visceral fat regions; calculating changes in area and / or volume of each tissue and changes in HU value based on the output results of the same subject at different time points; performing longitudinal quantitative analysis and comparison based on a timeline; and outputting visualized labeled results. This invention assesses the tissue regions and changes of three core components: muscle, subcutaneous fat, and visceral fat. It quantifies the assessment results using multiple dimensions such as pixel count, actual physical area or volume, grayscale density, and standard deviation. The assessment is comprehensive, objective, and repeatable, meeting the needs of precise clinical assessment. It can intuitively identify key pathological changes such as muscle loss and fat infiltration, providing a reliable basis for early intervention.